Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jul 21;18(7):e0289117. doi: 10.1371/journal.pone.0289117

Investigation of anti-proliferative and anti-angiogenic properties of Parkia javanica bark and fruit extracts in zebrafish

Rasik Dhakal 1, Krithika Kalladka 1, Achinta Singha 2, Dechamma Pandyanda Nanjappa 1, Jeshma Ravindra 1, Rajeshwari Vittal 1, Samir Kumar Sil 2,*, Anirban Chakraborty 1, Gunimala Chakraborty 1,*
Editor: Sehrish Sadia3
PMCID: PMC10361473  PMID: 37478119

Abstract

The use of herbal products as traditional medicines has been a practice in India for centuries. Due to high ethnic diversity, the pool of herbal medicines is enormous, and they are often preferred over modern medicines in certain parts of the country. Cancer is one of the major non-communicable diseases affecting people worldwide. Despite considerable research, cancer is a disease that is still not understood completely, and there have been constant efforts towards the identification of novel drugs or approaches in cancer management. Parkia javanica, an important medicinal plant and a rich source of flavonoids and terpenoids, is widely studied for its antioxidant and anti-inflammatory activities. Traditionally, the fruit and bark extracts of P. javanica find use as home remedy for dysentery and piles in NE India. Moreover, the fruits are consumed by the people of North-East (NE) India as vegetables, either in steamed or cooked form. In this study, crude extracts of P. javanica fruit and bark were obtained, the sub-lethal dose was determined and were then analyzed for anti-proliferative and anti-angiogenic properties using a battery of assays in zebrafish embryos. The sub-lethal concentration 50 (LC50) was found to be 28.66 mg/L and 346.66 mg/L for bark and fruit extract respectively, indicating a decreased toxicity of the fruit extract compared to that of the bark. The anti-proliferative and anti-angiogenic properties were more pronounced for the fruit extract compared to the bark extract. Although preliminary, the results of the study suggest that P. javanica fruits possess potent anti-angiogenic and anti-proliferative properties, which can be further studied for the isolation of active phytochemicals for use as therapeutic agents.

1. Introduction

For centuries, India has been a hub for herbal medicines and a major driving force for the success of eastern medicine. Due to the high ethnic diversity, the pool of herbal medicines is enormous in India. Parkia javanica (PJ), commonly called yongchak in Manipuri, is one of the widely used medicinal plants in North-East India. Parkia fruits are used as home remedies for dysentery and piles or as vegetables in steamed or cooked form [1, 2]. P. javanica extracts are known for antioxidant activity [3, 4], and anticarcinogenic properties [4, 5].

One of the important hallmarks of malignant tumors is angiogenesis, the process of formation of new blood vessels from the native vasculature. Tumor cells grow at a rapid pace and are generally hypoxic. Thus, for delivering nutrition and oxygen to the hypoxic microenvironment, it requires synthesis of new blood vessels [6]. Tumor cells secrete VEGF that binds with VEGF receptor-1 and VEGF receptor-2, which are expressed on vascular endothelial cells and increases angiogenesis. Induction of angiogenesis by tumor cells is not only for nutrition and oxygen supply but also for ensuring successful metastasis of malignant cells. The genes responsible for production of VEGF are up regulated by oncogene expression [7, 8]. Since tumor growth and movement to distant sites is dependent on angiogenesis [9], inhibition of angiogenesis can be a therapeutic approach.

Tumor cells divide rapidly and release various growth factors in the microenvironment that promote cell proliferation [10]. Therefore, targeting these characteristics of tumor cells using natural extracts can be possible way ahead towards development of new therapeutics. A vast majority of western medicines are derived from plant-based compounds, and hence there are numerous possibilities for herbal treatment in modern era. Numerous in vitro studies have been conducted on putative plant-based drugs, but these studies lacked the perspective of an in vivo setting with its multifactorial factors and systemic approach to drug testing. Plant-based products are believed to have lesser side effects compared to modern medicines and the Indian traditional system documents the use of many such compounds that are used for treating various conditions, including cancer. Modern anti-cancer drugs have many side effects and drug resistance is a common phenomenon. Thus, targeting cancer through alternative approaches and identification of plant-derived compounds for such approaches are highly relevant. Although cell culture provides information about potential side effects, multicellular model gives us multifactorial systemic effects. So, for the compound to be safe in market use, the toxicity profiling should be done in systems with a physiological relevance [11]. Therefore, identification of inhibitors for angiogenesis and regulators for pro and anti-apoptotic proteins from natural sources holds great promise in cancer management.

Zebrafish (Danio rerio), a small tropical fish, serves as an excellent model for disease modeling because of its cost-effective maintenance, rapid fertility, ease of growth and amenability to large scale phytochemical screening at reasonable cost [12]. The in-vitro model systems provide information about potential side effects, but multicellular animal-based study provides the physiological relevance. Therefore, it is essential to determine the toxicity of compounds at physiological level and model systems like zebrafish can serve as useful in vivo tools to support for the selection of the safest lead molecules in the path of drug discovery process [13]. For instance, the availability of Kdrl:eGFP transgenic zebrafish model system is one of the important research tool for angiogenesis study [14, 15]. In the present study, we evaluated the potential effects of anti-angiogenesis, anti-proliferative and apoptotic activity of Parkia javanica bark and fruit extract in zebrafish embryos.

2. Materials and methods

2.1. Sample collection and extract preparation

The fresh bark and fruit of Parkia javanica (Lam.) Merr. were obtained from North eastern state of Tripura, India. The identification and authentication of the plant species was done by a certified botanist. The details are given in S1 Table. Briefly, P. javanica bark and fruits were cleaned with distilled water, then chopped into tiny pieces, and shaded dried for 3–4 weeks. The dried materials were then ground, and 200 gm of powdered bark and fruits was mixed with 600 mL of methanol to prepare the methanolic extract of PJ bark (MEPJB) and fruits (MEPJF). The solution was kept in a shaker at room temperature for 48 hours followed by filtration at least 3–4 times with Whatman filterpaper-1. Then the filtered solution was concentrated by evaporating the pure methanol solvent from the solution in a rotary evaporator at 45°C. Finally, the concentrated solution was dried at 4°C to eliminate the methanol from the extract. The % yield of the extract was 8.896% and was stored at -20°C [16].

2.2. Zebrafish husbandry and rearing

Adult zebrafish were reared in the multilinking culture system with the ambient temperature maintained around at 28.5°C with a fixed 14/10 h day/night cycle. The fishes were kept pairwise in the breeding chambers overnight. Embryos were collected the next morning and transferred to fresh petri dishes containing E3 media and kept in incubator at 28.5°C temperature [17]. The embryos were segregated at 10 hours post fertilization and exposed to both the compounds.

2.3. Determination of sub lethal concentration (LC50)

To determine the LC50 of both the extracts, a semi-static methodology was followed, where media was changed twice in a day along with the compound. Probit analysis was used to find the LC50 value of both extracts. The upper limit was the concentration where all embryos died (LC100) and lower limit was the concentration at which all embryos were survived (LC0). The embryos (n = 10) were segregated and put in a 12-well micro titer plate and exposed to both the compounds at 10 hpf. The experiment was conducted in triplicates with one unexposed control group. 24 hours post exposure, embryos were observed for survivability and were imaged using a stereomicroscope (Leica S9D, Germany).

2.4. Evaluation of developmental toxicity of bark and fruit extracts

Developmental toxicity of P. javanica bark and fruit extracts were assessed by observing the embryos for five days and noting the sub lethal and sub-sub lethal end points at each day of post fertilization. Cardiotoxicity, neurotoxicity, hepatotoxicity and hatching ability were examined at 1/10th and 1/100th of sub lethal concentration. 10 embryos were used for each concentration and were imaged using a stereomicroscope (Leica S9D, Germany) and compared with control. All the experiments were performed in triplicates.

2.5 Assessment of anti-angiogenesis property of P. javanica bark and fruit extracts

To assess the anti-angiogenic property of both the extracts, transgenic zebrafish line (Tg (Kdrl:GFP)) where GFP protein expresses under the control of the promoter of the kdrl gene was used. Tg (Kdrl:GFP) embryos were treated with sub lethal concentration of both bark and fruit extracts (1/10th and 1/100th) at 10 hpf and compared with control. All the embryos were treated with 10 μl of phenylthiourea (0.003%) to prevent pigmentation. The treated embryos were observed for intersegmental vessels (ISV) and sub intestinal veins (SIV) at 48 and 72 hpf using fluorescent microscope (Leica 4500, Germany). The analysis of image was done using ImageJ software and fluorescence intensity was compared using CTCF value. [CTCF = Integrated Density–(Area of selected cell X Mean fluorescence of background readings)] [18].

2.6. Evaluation of anti-proliferative activity of P. javanica bark and fruit extracts

The anti-proliferative activity of both the extracts was evaluated on zebrafish AB line embryos using pH3-histone staining [20]. Phosphorylation of serine10 residue in H3 histone tail is the characteristics feature of DNA condensing during mitosis. So, phosphorylated histone H3 antibody staining is done to detect the proliferation of cells. The healthy embryos were exposed with both extracts at 10hpf and dechorionation was performed at 24 hpf, followed by fixation of the embryos in 4% PFA (paraformaldehyde). The pH3 staining was done at 6 hours post fixation. In brief, the excess PFA and the organic waste was removed and washed with 1X PBS and acetone respectively. Permeability of cells was increased by using PBST and to avoid non-specific binding, blocking solution was used. Primary antibody was introduced and incubated overnight at 4°C. On the second day, secondary antibody was added, which is conjugated with peroxidase enzyme. Peroxidase conjugated enzyme uses hydrogen peroxide as a substrate and oxidize the DAB solution (3,3’diaminobenzene). Imaging was done using stereomicroscope (Leica S9D, Germany).

2.7. Assessment of apoptotic activity of P. javanica bark and fruit extracts

Apoptotic activity of the extracts was evaluated using acridine orange staining in tp53-/- mutant embryos. Acridine orange is an organic nucleic acid-specific dye that can easily cross the cellular membrane and bind with the dsDNA. After binding with dsDNA, it emits green fluorescence. The embryos were exposed to the extracts at 10hpf along with PTU (0.003%) to prevent pigmentation. Post exposure for 24 hpf, 1.5μl of acridine orange (0.5X) was added to 3 ml of E3 media. The embryos were incubated in dark for 30 minutes and post incubation embryos were washed with E3 media and observed under fluorescent microscope (Leica 4500, Germany). The analysis of image was done using ImageJ software and fluorescence intensity was calculated using CTCF value. [CTCF = Integrated Density–(Area of selected cell X Mean fluorescence of background readings)].

2.8. Chemicals and reagents

Acradine Orange (Sigma-Aldrich, Germany), phenyl 2-thiourea (PTU) (Sigma-Aldrich, Germany), 2’,7’-dichlorodihydrofluorescein diacetate or H2DCFD (Sigma-Aldrich, Germany) Dimethylsulfoxide (DMSO) (Himedia, India Pvt, Ltd.), KCl (Merck Life Science Germany.), CaCl2(Thermo fisher scientific, India Pvt, Ltd.), NaCl (Himedia, India Pvt, Ltd.), MgSO4 (Loba Chemie India Pvt, Ltd.).

2.9. Statistical analysis

The differences in values between the control and crude-extract treated embryos were checked for significance by estimating the p-value using a t-test. A p value of <0.05 was considered to be statistically significant.

3. Results

3.1 Effects of P. javanica extracts on development

The LC50 concentration of bark extract was found to be 28.66 mg/L as compared to fruit extract that showed a much higher value of 346.6 mg/L, suggesting it to be more toxic compared to that of fruit extract. In case of P. javanica (PJ) bark extract, no mortality was observed at a concentration below 23 mg/L (LC0) whereas for PJ fruit extract LC0 was below 250 mg/L. The zebrafish embryos treated with 1/10th concentration of LC50 for PJ bark extract showed normal heartbeat, hatching ability and increased pigmentation, however subtle abnormalities were observed in pancreas at day 5 post fertilization. Intense yellow pigmentation of the intestinal bulb, along with slow development of swim bladder, was observed in the bark extract-treated embryos when compared to control (Fig 1A). However, unlike bark, PJ fruit extract showed developmental defects at 1/10th (Fig 1B) and 1/100th of sub lethal dose (Fig 1C). Exposure with 1/10th dose of bark and fruit extracts showed an effect on the heartbeat, with a delay in the treated embryos. However, the decrease in heartbeat was statistically significant only for the fruit extract and not for the bark extract (Fig 1D). At 1/10th of sub-lethal dose, although there was no difference in the hatching ability in both fruit and bark extract treated embryos, compared to controls (Fig 1D), the embryos showed developmental defects leading to death after 3day post fertilization (dpf). However, the 1/100th dose of fruit extract showed no cardiotoxicity, neurotoxicity even after hatching (3 dpf) although swim bladder abnormality was observed (Data not shown). Since the embryos treated with 1/10th concentration of LC50 of fruit extract could not survive beyond 3 dpf, 1/100th concentration of the sub-lethal dose was used for all other experiments.

Fig 1. Effect of Parkia javanica bark and fruit extracts on developmental toxicity.

Fig 1

(A) The PJ bark extracts showing morphological defects with 1/10th concentration (2.86 ppm) of LC50 compared to control group at different days of post fertilization. (B) & (C) represent the morphological defects of embryos treated with PJ fruit extract at 1/10th and 1/100th concentration of LC 50 i.e. 34.6 ppm and 3.46 ppm. (D) The cardiotoxicity of PJ fruit and bark in both control and treated groups was presented in (a) & (b), whereas the hatching ability was presented in (c) & (d). Asterisk indicates p-value <0.05.

3.2 Evaluation of anti-angiogenesis property

The anti-angiogenic property of PJ bark and fruit extracts was evaluated in a transgenic zebrafish model Tg(Kdrl:GFP) expressing GFP under the control of the promoter of kinase insert domain receptor like (kdrl). The antiangiogenic activity was checked at 1/10th and 1/100th of LC50 concentration of PJ bark and fruit extract (2.86 mg/L of bark extract and 3.46 mg/L of fruit extract) as these concentrations did not show any effect on embryonic development. As shown in Fig 2A the bark extract had less effect on the formation of ISVs at 48 hpf, but at 72 hpf the treated embryos showed less branching of SIV compared to control, which is indicated by white arrow (Fig 2C). The CTCF value of treated embryos as calculated according to the signal intensity of GFP was also lesser compared to control at both 48 hpf (Fig 2B) and 72 hpf (Fig 2D). However, the difference was not statistically significant. In case of fruit extract, the treated embryos had effects on the formation of ISVs at 48 hpf (Fig 2E), the GFP intensity of the treated embryos was also less compared to the control. The CTCF value for treated embryos was found to be significantly lesser than the control embryos (Fig 2F).

Fig 2. Anti-angiogenic effects of Parkia javanica bark and fruit extract on zebrafish transgenic line Tg(kdrl:GFP).

Fig 2

(A) The anti-angiogenic activity of PJ bark extract in transgenic Tg(kdrl:GFP) line with 2.86 ppm at 48 hpf. (B) Graph depicting the CTCF values for PJ bark extract exposed to Tg(kdrl;GFP) embryos, identifying the intra segmental vessels at 48 hpf. (C) The effect of PJ bark extract (2.86 ppm) on Tg(kdrl:GFP) model in SIV basket at 72hpf. (D) The CTCF values for PJ bark extract exposed to Tg(Kdrl;GFP) embryos, identifying the intestinal basket at 72 hpf. (E) Representative images of Tg(kdrl:GFP) trunk ISVs (a: control; b: treated) with 3.46 ppm PJ fruit extract at 48 hpf, (F) Graph depicting the CTCF values for PJ fruit extract exposed to Tg(Kdrl;GFP) embryos, identifying the intra segmental vessels at 48 hpf. Asterisk indicates p-value <0.05.

3.3 Evaluation of anti-proliferative activity

The anti-proliferative activity of PJ bark and fruit extracts was assessed using wild type zebrafish embryos. The PJ fruit extract was found to be anti-proliferative at both 1/10th and 1/100th concentration of sub-lethal dose whereas PJ bark extract did not show any anti-proliferative activity (Fig 3). The cell proliferation was evaluated by counting the number of brown dots, each representing a cell positive for pH3, a proliferation marker.

Fig 3. Anti-proliferative effects of Parkia javanica bark and fruit extract on zebrafish.

Fig 3

(A) The number of cells represented in brown dots has decreased in embryos treated with fruit extract compared to the control in 1/10th of LC50 concentration (34.6 ppm). (B) The number of cells represented in brown dots in embryos treated with bark extract with 1/10th concentration (2.86 ppm) did not show any difference compared to control.

3.4 Assessment of apoptotic activity of Parkia javanica bark and fruit extracts

The apoptotic activity of PJ bark and fruit extracts were assessed by using tp53-/- mutant zebrafish embryos. Embryos treated with both the extracts showed more apoptotic cells compared to the control, indicated by an increase in the fluorescence intensity in the treated embryos (Fig 4A and 4C The corresponding CTCF values of treated PJ bark and fruit at 2.86 mg/L and 34.6mg/L respectively was higher compared to control, which indicates that both the extracts can induce cellular apoptosis (Fig 4B and 4D). However, statistically significant values were seen only for fruit extract.

Fig 4. Pro-apoptotic effect of P. javanica bark and fruit extracts.

Fig 4

(A) Representative images of embryos exposed to UV and treated with 2.86 ppm of bark extract showing pro-apoptosis compared to untreated embryos. (B) Graph showing the total cell fluoresce intensity exposed to 2.86 ppm PJ bark extract at 48 hpf embryos. (C) The embryos exposed to UV and treated with 3.46 ppm of fruit extract showing pro-apoptosis compared to untreated embryos. (D) Graph showing corrected total cell fluoresce of 48 hpf embryos exposed to 3.46 ppm PJ bark extract. Asterisk indicates p-value <0.05.

4. Discussion

Zebrafish model system has proved to be a reliable in- vivo model system in recent progresses in drug discoveries, cancer research, and toxicity studies [19, 20]. The advantage of zebrafish over the other of animal model is due to its short lifespan, high fecundity, embryonic transparency, and low set up cost. The ability to absorb small molecules diluted in the surrounding water through their skin, gut, and gills is also another interesting feature of zebrafish [21]. The genus Parkia have about 34 different species and most of them are pharmacologically active [22]. The Parkia plants are consumable right from the inflorescence, fruits, the mature seeds, and are known to be very rich in protein and minerals. Victoria and co-researchers found that PJ seed extract can induce cytotoxicity in HeLa and MCF-7 cancer cell lines [23]. The aqueous and methanol extract of PJ fruit extract have been shown to induce cytotoxicity in MDA-MB435S, sarcoma-180, A549, and AGS cell lines [24]. However, there are no toxicity reports available on in vivo model system. We investigated the toxicity of PJ extracts on zebrafish and the sub-lethal doses of bark and fruit extract were found to be 28.66mg/L and 346.7 mg/L respectively with no developmental defects except for differences in pigmentation and coloration of intestinal bulb whose etiology requires further investigation. The sub lethal doses of LC50 of the extracts (fruit- 34.6 mg/L, 3.46 mg/L and bark- 2.86 mg/L) was used for understanding the biological activity of the compound such as developmental toxicity, and anticancer activity. The 1/100th concentration of the sub-lethal dose was found to be safer for embryos throughout the experiment.

Neovascularization or angiogenesis is the key feature in solid tumors. Therefore, characterization of anti-angiogenic property of any compounds is considered as a promising approach to cancer therapies. Parkia speciosa fresh pod extract (methanol) showed more than 50 percent significant inhibition of vascularization in rat aortae [22]. In our study, P. javanica bark extract did not show any anti-angiogenic property in zebrafish at 1/10th of sub lethal concentration. However, 1/100th sub-lethal dose of PJ fruit extract showed prominent anti-angiogenic activity and developmental defects such as increased pigmentation, slow development of swim bladder, cardiotoxicity, neurotoxicity.

Cancer cells have hallmark of sustained cell proliferation. Parkia roxburghii seed extract was shown to inhibit proliferation of B-cell hybridoma cell line [25], and HepG2 cells without influencing the normal cells [26]. Similarly, methanol extracts of Parkia filicoidea and Parkia biglobosa were found to exhibit anti-proliferative activities on BT-20 and T-549 (prostate cancer), SW-480 (colon cancer) and PC-3 (acute T cell leukemia Jurka) at concentration-dependent manner [27]. The phosphorylated histone H3 protein are always found in metaphasic chromosomes and by estimating the concentration phosphorylated H3 histone protein one can predict the rate of cell division in an organism [28]. In this study, immune staining was performed using anti-phosphorylated H3 histone protein antibody, which binds to the phosphorylate H3 tail during the cell division. A higher dot indicates proper chromatin condensation. In the case of PJ fruit extract both the sub-lethal concentration showed anti-proliferative activity indicated by the presence of lesser positive dots in treated embryos compared to control embryos.

Apoptosis is a popular target of many cancer treatment strategies. Patra and group found that the PJ extract significantly lowered the tumor volume and tumor weight compared to untreated group [24]. In the present study, apoptosis inducing ability of PJ extract was evaluated in zebrafish model and the results showed a remarkable increase in fluorescence when exposed to UV radiation suggesting that the extracts has pro-apoptotic effects. Other studies also showed pro-apoptotic activity of PJ seed extracts in cancer cells and bark extracts in colon cancer cell lines [26]. The findings of this study support the evidence for apoptosis inducing activity of PJ. In this study, crude extracts were used to evaluate the anti-proliferative and anti-angiogenic activity of PJ. Further investigation is required to confirm the molecular mode of action of PJ extracts and identification of the active ingredient. We did attempt the characterization of the PJ bark and the fruit extract through GC-MS. In case of PJ fruit, a total of 14 peaks were seen, suggesting the presence of 14 compounds and one of the them was Lupeol, a well-characterized dietary triterpene (member of the phytosterol family) with known anti-inflammatory and anti-cancer properties [29]. In case of the bark extract, a total of 15 compounds were identified, and one of the major compounds identified was D-allose, known for its anti-cancer and anti-metabolic syndrome effects [30]. The details of the GC-MS analysis are shown as S2 and S3 Tables. Parkia javanica fruits can be considered as important dietary components to prevent cancer development. Future studies can also be focused on isolation and characterization of phytochemicals from PJ fruits as potential anti-cancer compounds.

5. Conclusion

The study has focused on the usage of zebrafish as an effective in-vivo system animal model for high throughput screening of natural compounds. The study revealed that Parkia javanica fruit extract has anti-angiogenic, anti-proliferative activities compared to the bark extract. Future work should be focused on identifying and isolating the active phytochemicals from this crude extract and evaluating their therapeutic potential that will pave the way for the development of novel anti-cancer drugs.

Supporting information

S1 Table. Taxonomic identification of Parkia javanica.

(DOCX)

S2 Table. GC-MS library of Parkia javanica fruit extract.

(DOCX)

S3 Table. GC-MS library of Parkia javanica bark extract.

(DOCX)

S1 File

(DOCX)

Acknowledgments

We thank NITTE (deemed to be university) for providing the research infrastructure and resources for carrying out this work.

Data Availability

All relevant data are within the paper.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Khumbongmayum A.D., Khan M., and Tripathi R., Ethnomedicinal plants in the sacred groves of Manipur. 2005. [Google Scholar]
  • 2.Khan M.H. and Yadava P., Antidiabetic plants used in Thoubal district of Manipur, Northeast India. 2010. [Google Scholar]
  • 3.Jivad N. and Rabiei Z., A review study on medicinal plants used in the treatment of learning and memory impairments. Asian Pacific journal of tropical biomedicine, 2014. 4(10): p. 780–789. [Google Scholar]
  • 4.Chanu K., Ali M., and Kataria M., Antioxidant activities of two medicinal vegetables: Parkia javanica and Phlogacanthus thyrsiflorus. Int J Pharm Pharm Sci, 2012. 4(1): p. 102–6. [Google Scholar]
  • 5.Tahira T., et al., The inhibitory effect of thioproline on carcinogenesis induced by N-benzylmethylamine and nitrite. Food and chemical toxicology, 1988. 26(6): p. 511–516. doi: 10.1016/0278-6915(88)90003-8 [DOI] [PubMed] [Google Scholar]
  • 6.Pandya N.M., Dhalla N.S., and Santani D.D., Angiogenesis—a new target for future therapy. Vascular pharmacology, 2006. 44(5): p. 265–274. doi: 10.1016/j.vph.2006.01.005 [DOI] [PubMed] [Google Scholar]
  • 7.Kim S.-Y., Cancer energy metabolism: shutting power off cancer factory. Biomolecules & Therapeutics, 2018. 26(1): p. 39. doi: 10.4062/biomolther.2017.184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Carmeliet P., VEGF as a key mediator of angiogenesis in cancer. Oncology, 2005. 69(Suppl. 3): p. 4–10. doi: 10.1159/000088478 [DOI] [PubMed] [Google Scholar]
  • 9.Folkman J., Tumor angiogenesis: therapeutic implications. New england journal of medicine, 1971. 285(21): p. 1182–1186. doi: 10.1056/NEJM197111182852108 [DOI] [PubMed] [Google Scholar]
  • 10.Zafar S., Jain D., and Ahmad F.J., Metallic nanoparticles in drug delivery: concepts, challenges, and current advancement, in Multifunctional Nanocarriers. 2022, Elsevier. p. 121–148. [Google Scholar]
  • 11.Parasuraman S., Toxicological screening. Journal of pharmacology & pharmacotherapeutics, 2011. 2(2): p. 74. doi: 10.4103/0976-500X.81895 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hason M. and Bartůněk P., Zebrafish models of cancer—new insights on modeling human cancer in a non-mammalian vertebrate. Genes, 2019. 10(11): p. 935. doi: 10.3390/genes10110935 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Asante-Duah D.K., Public health risk assessment for human exposure to chemicals. Vol. 6. 2002: Springer. [Google Scholar]
  • 14.Chiavacci E., et al., The zebrafish/tumor xenograft angiogenesis assay as a tool for screening anti-angiogenic miRNAs. Cytotechnology, 2015. 67(6): p. 969–975. doi: 10.1007/s10616-014-9735-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Xin Q.-q., et al., Paeoniflorin promotes angiogenesis in a vascular insufficiency model of zebrafish in vivo and in human umbilical vein endothelial cells in vitro. Chinese journal of integrative medicine, 2018. 24(7): p. 494–501. doi: 10.1007/s11655-016-2262-2 [DOI] [PubMed] [Google Scholar]
  • 16.Harborne A., Phytochemical methods a guide to modern techniques of plant analysis. 1998: springer science & business media. [Google Scholar]
  • 17.Westerfield M., The zebrafish book: a guide for the laboratory use of zebrafish. http://zfin.org/zf_info/zfbook/zfbk.html, 2000. [Google Scholar]
  • 18.El-Sharkawey A., Calculate the Corrected Total Cell Fluorescence (CTCF). Calculate the Corrected Total Cell Fluorescence (CTCF), 2016. [Google Scholar]
  • 19.Hernández-Silva D., et al., Virtual screening and zebrafish models in tandem, for drug discovery and development. Expert Opinion on Drug Discovery, 2022(just-accepted). doi: 10.1080/17460441.2022.2147503 [DOI] [PubMed] [Google Scholar]
  • 20.Cassar S., et al., Use of zebrafish in drug discovery toxicology. Chemical research in toxicology, 2019. 33(1): p. 95–118. doi: 10.1021/acs.chemrestox.9b00335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.McGrath P, Li CQ. Zebrafish: a predictive model for assessing drug- induced toxicity. Drug Discov Today. 2008.13(9–10):394–401. doi: 10.1016/j.drudis.2008.03.002 [DOI] [PubMed] [Google Scholar]
  • 22.Saleh M.S., et al., Genus parkia: phytochemical, medicinal uses, and pharmacological properties. International Journal of Molecular Sciences, 2021. 22(2): p. 618. doi: 10.3390/ijms22020618 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Khangembam V.C., et al., Evaluation of apoptosis inducing ability of Parkia javanica seed extract in cancer cells. Indian Journal of Pharmaceutical Sciences, 2018. 80(6): p. 1069–1077. [Google Scholar]
  • 24.Patra K., et al., Parkia javanica extract induces apoptosis in S-180 cells via the intrinsic pathway of apoptosis. Nutrition and Cancer, 2016. 68(4): p. 689–707. doi: 10.1080/01635581.2016.1158298 [DOI] [PubMed] [Google Scholar]
  • 25.Kaur N., et al., Two novel lectins from Parkia biglandulosa and Parkia roxburghii: isolation, physicochemical characterization, mitogenicity and anti-proliferative activity. Protein and peptide letters, 2005. 12(6): p. 589–595. doi: 10.2174/0929866054395725 [DOI] [PubMed] [Google Scholar]
  • 26.Chanu K.V., et al., Phytochemical analysis and evaluation of anticancer activity of Parkia javanica seeds. The Pharma Innovation, 2018. 7(5, Part E): p. 305. [Google Scholar]
  • 27.Fadeyi S.A., et al., In vitro anticancer screening of 24 locally used Nigerian medicinal plants. BMC Complementary and Alternative Medicine, 2013. 13(1): p. 1–10. doi: 10.1186/1472-6882-13-79 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hans F. and Dimitrov S., Histone H3 phosphorylation and cell division. Oncogene, 2001. 20(24): p. 3021–3027. doi: 10.1038/sj.onc.1204326 [DOI] [PubMed] [Google Scholar]
  • 29.Saleem M, Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Letters, 2009. 285(2): 109–115. doi: 10.1016/j.canlet.2009.04.033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Shintani H et al., D-Allose, a Trace Component in Human Serum, and Its Pharmaceutical Applicability. International Journal of Applied Biology and Pharmaceutical Technology, 2020. 11: 200–213. [Google Scholar]

Decision Letter 0

Sehrish Sadia

18 Apr 2023

PONE-D-22-33455

Investigation of anti-proliferative and anti-angiogenic properties of Parkia javanica bark and fruit extracts in zebrafish

PLOS ONE

Dear author

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

​Please submit your revised manuscript by May 26 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Sehrish Sadia

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Thank you for stating the following in the Acknowledgments/ Funding Section of your manuscript:

“The financial support from NITTE (Deemed to be University) through the intramural research grant.”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“The author(s) received no specific funding for this work”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the manuscript “Investigation of anti-proliferative and anti-angiogenic properties of Parkia javanica bark and fruit extracts in zebrafish” authors have compared the anti-proliferative and anti-angiogenic properties of bark and fruit extracts of Parkia javanica in the zebrafish model. In addition, authors have reported the efficacy of fruit extract in inhibiting the proliferation of cells compared to bark extract. Although the results are interesting, it is a preliminary study and requires extensive studies in appropriate model systems to demonstrate the anti-proliferative and anti-angiogenic properties. Furthermore, as authors have also mentioned, identification of active ingredients is lacking in this manuscript. At least authors would have determined the composition of the extract by LC-MS-MS. In light of these shortcomings, I recommend the publication of this manuscript only after including the composition analysis of the extract and addressing the following comments

Major comments

1. Did a certified botanist authenticate the plant? If so provide the authentication certificate and the photograph of the specimen used for authentication as supplemental data. Mention the full name of the plant Parkia javanica (Lam.) Merr.

2. Did authors use whole fruit for the extract preparation? Or they have separated the skin and seeds?

3. How much is the yield of methanolic extract?

4. Error bars are missing in all the bar graphs. Did authors determine the statistical significance? If so, add the information

Minor comments

Line #94. Authors have mentioned that they have prepared extracts from bark as well as fruit, but the name MEPJB, referring extract from bark, was only mentioned. Did authors have labeled the extract fruit as MEPJF? If so, include it in the methods section.

Line #129: Mention the concentration of polythiourea

Reviewer #2: [1]. The abstract does not provide much context for why the study is important or what is already known about the topic. It would be helpful to include a brief introduction that explains the prevalence and anti-proliferative and anti-angiogenic properties, and why finding new treatments is important.

[2]. The abstract does not provide information on the sample size and experimental design of the study, which is an important factor in determining the reliability of the results. Providing more information on these aspects would help readers to understand the study's rigor.

[3]. In line 52, the Manipuri name of the plant is wrong.

[4]. What about the authentication of plant material?

[5]. Voucher specimen no is missing in the MS.

[6]. A list of chemical and reagent are missing.

[7]. While using the rotary evaporator, the temperature should not be more than 45-48 oC but in the current work 60 oC was used which is not acceptable.

[8]. As mentioned in lines 97-99 “Finally, the concentrated solution was lyophilized at 4°C to eliminate the methanol..”, but lyophilization is important for removing the water traces, not the methanol.

[9]. The % yield of the extract is missing.

[10]. There is no details section of statistical analysis.

[11]. The authors did not clarify the standard drug used in the study.

[12]. It would be good if the phyto constituent of the active extract can be detected by HPLC or LC-MS or some other analytical techniques.

[13]. The presentation of the results and discussion is not well organized.

[14]. The conclusion is not effective.

[15]. There are many syntax errors, confusing sentences, and grammatical mistakes in the manuscript. The manuscript critically needs revision.

[16]. The English of the manuscript is not up to the standard of the journal.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: SubbaRao V. Madhunapantula

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jul 21;18(7):e0289117. doi: 10.1371/journal.pone.0289117.r002

Author response to Decision Letter 0


5 Jun 2023

Response to reviewer’s comments

Journal name: PLOS ONE

Manuscript ID: PONE-D-22-33455

Title: Investigation of anti-proliferative and anti-angiogenic properties of Parkia javanica bark and fruit extracts in zebrafish

All the modifications in the revised manuscript are highlighted in yellow colour.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: No

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1:

In the manuscript “Investigation of anti-proliferative and anti-angiogenic properties of Parkia javanica bark and fruit extracts in zebrafish” authors have compared the anti-proliferative and anti-angiogenic properties of bark and fruit extracts of Parkia javanica in the zebrafish model. In addition, authors have reported the efficacy of fruit extract in inhibiting the proliferation of cells compared to bark extract. Although the results are interesting, it is a preliminary study and requires extensive studies in appropriate model systems to demonstrate the anti-proliferative and anti-angiogenic properties. Furthermore, as authors have also mentioned, identification of active ingredients is lacking in this manuscript. At least authors would have determined the composition of the extract by LC-MS-MS. In light of these shortcomings, I recommend the publication of this manuscript only after including the composition analysis of the extract and addressing the following comments

Response: Thank you for your valuable suggestion. The comments are well taken. We have carried out GC-MS analysis of the extracts to understand the composition of the crude extracts obtained from the fruit and the bark. However, in this manuscript the focus was on analysing the effects of the crude extracts. In the revised manuscript, the composition analysis of the crude extracts have been mentioned briefly in the discussion section (Lines 264-271) and the details are included as supplemental data (Table 2 and 3).

Major comments

1. Did a certified botanist authenticate the plant? If so provide the authentication certificate and the photograph of the specimen used for authentication as supplemental data. Mention the full name of the plant Parkia javanica (Lam.) Merr.

Response: We thank the reviewer for this suggestion. Yes, the taxonomic identification of the plant was done by a certified botanist , Dr H.J. Chowdhary, the joint director at the Central National Herbarium, Botanical Survey of India, Shibpur, Howrah, West Bengal, India. As per the suggestion of the reviewer, the details of this identification are shown as supplemental table 1.

2. Did authors use whole fruit for the extract preparation? Or they have separated the skin and seeds?

Response: We thank the reviewer for this comment. Yes, the whole fruit, without separating the skin and the seeds was used for the crude extract preparation.

3. How much is the yield of methanolic extract?

Response: Thank you for your valuable suggestion. The percentage yield is now mentioned in the materials section in the revised manuscript. (Line 110)

4. Error bars are missing in all the bar graphs. Did authors determine the statistical significance? If so, add the information

Response: We thank the reviewer for this valuable suggestion. As per the suggestions, the error bars are included in the bar graphs for all the figures.

Minor comments

Line #94. Authors have mentioned that they have prepared extracts from bark as well as fruit, but the name MEPJB, referring extract from bark, was only mentioned. Did authors have labelled the extract fruit as MEPJF? If so, include it in the methods section.

Response: Thank you for your valuable suggestion. Corrections have been made in the revised manuscript according to the reviewer’s suggestion (Lines 105-106).

Line #129: Mention the concentration of polythiourea

Response: Thank you for your valuable suggestion. Corrections have been made in the revised manuscript according to reviewer’s suggestion the concentration of PTU is indicated in the method section (Line 141).

Reviewer #2:

[1]. The abstract does not provide much context for why the study is important or what is already known about the topic. It would be helpful to include a brief introduction that explains the prevalence and anti-proliferative and anti-angiogenic properties, and why finding new treatments is important.

Response: We thank the reviewer for this suggestion. We have now added a few sentences highlighting the relevance of the study (Lines 23-26). However, since the abstract has certain word limits, we couldn’t add to many information there. However, explanations on why new treatments are important are mentioned in the introduction part (Lines 72-82).

[2]. The abstract does not provide information on the sample size and experimental design of the study, which is an important factor in determining the reliability of the results. Providing more information on these aspects would help readers to understand the study's rigor.

Response: We thank the reviewer for this suggestion. For a study of this nature, sample size is not very informative as the focus was on determining the anti-cancer properties of crude extracts of fruit and bark of a plant, Parkia javanica. However, as per the suggestion, we have now included a few sentences about the experimental design in the abstract of the revised manuscript (Lines 31-33).

[3]. In line 52, the Manipuri name of the plant is wrong.

Response: Thank you for your valuable suggestion. Corrections in the local name of the plant have been made in the revised manuscript according to reviewer’s suggestion (Line 56)

[4]. What about the authentication of plant material?

Response: Thank you for your valuable suggestion. The details of authentication of the plant material have been added in the revised manuscript according to reviewer’s suggestion as a supplemental data and the same has been mentioned in the methods section. (Lines 101-102).

[5]. Voucher specimen no is missing in the MS.

Response: Thank you for your valuable suggestion. The details of voucher specimen no has been added as a supplemental data in the revised manuscript.

[6]. A list of chemical and reagent are missing.

Response: Thank you for your valuable suggestion. The list of chemical and reagents used are incorporated in the materials and methods section in the revised manuscript (Lines 175-179).

[7]. While using the rotary evaporator, the temperature should not be more than 45-48 oC but in the current work 60 oC was used which is not acceptable.

Response: Thank you for your valuable correction. The temperature for the rotary evaporator was fixed at 45oC. It was a typographical error, it has been modified in the revised manuscript.

[8]. As mentioned in lines 97-99 “Finally, the concentrated solution was lyophilized at 4°C to eliminate the methanol..”, but lyophilization is important for removing the water traces, not the methanol.

Response: Thank you for your valuable correction. We have not lyophilized the samples. It was simply dried at 4C for completely removal of methanol. The word lyophilized have been replaced with dried in the revised manuscript (line 109).

[9]. The % yield of the extract is missing.

Response: Thank you for your valuable comment. The yield of the extract has been incorporated in the revised method section (Line 110).

[10]. There is no details section of statistical analysis.

The details of statistical significance is mentioned in the materials and methods section (Line 181-183).

[11]. The authors did not clarify the standard drug used in the study.

We would like to clarify here that there was no standard drug used in this study. The observations were compared between the embryos treated with crude extracts and those untreated.

[12]. It would be good if the phyto constituent of the active extract can be detected by HPLC or LC-MS or some other analytical techniques.

Response: Thank you for your valuable comment. The GC-MS composition of both the fruit and the bark extract are shown as supplementary data (Supplementary tables 2 and 3) in the revised manuscript.

[13]. The presentation of the results and discussion is not well organized.

Response: Thank you for your valuable comment. In the revised manuscript, the sections pertaining to the presentation of the results and the discussion were rephrased for better clarity.

[14]. The conclusion is not effective.

Response: Thank you for your valuable comment. The conclusion part has been rephrased.

[15]. There are many syntax errors, confusing sentences, and grammatical mistakes in the manuscript. The manuscript critically needs revision.

Response: Thank you for your valuable comment. As per the reviewer’s suggestion, the entire manuscript has been revised extensively to remove the syntax errors and grammatical errors.

[16]. The English of the manuscript is not up to the standard of the journal.

Response: Thank you for your valuable comment. The manuscript has been edited extensively to ensure that the language used is as scientific as possible and the usage of the vocabulary is as per the requirements of scientific journals.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: SubbaRao V. Madhunapantula

Reviewer #2: No

________________________________________

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Response to Reviewers comments.docx

Decision Letter 1

Sehrish Sadia

12 Jul 2023

Investigation of anti-proliferative and anti-angiogenic properties of Parkia javanica bark and fruit extracts in zebrafish

PONE-D-22-33455R1

Dear Author

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Sehrish Sadia

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

<quillbot-extension-portal></quillbot-extension-portal>

Acceptance letter

Sehrish Sadia

14 Jul 2023

PONE-D-22-33455R1

Investigation of anti-proliferative and anti-angiogenic properties of Parkia javanica bark and fruit extracts in zebrafish

Dear Dr. Chakraborty:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sehrish Sadia

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Taxonomic identification of Parkia javanica.

    (DOCX)

    S2 Table. GC-MS library of Parkia javanica fruit extract.

    (DOCX)

    S3 Table. GC-MS library of Parkia javanica bark extract.

    (DOCX)

    S1 File

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers comments.docx

    Data Availability Statement

    All relevant data are within the paper.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES